Fludarabine Phosphate is Used for treating patients with B-cell chronic lymphocytic leukemia (CLL). It was first introduced by Genzyme Corp in its drug Fludara on Apr 18, 1991. Other drugs containing Fludarabine Phosphate are Oforta, Fludarabine Phosphate. 12 different companies have introduced drugs containing Fludarabine Phosphate.

Fludarabine Phosphate Patents

Given below is the list of patents protecting Fludarabine Phosphate, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Oforta	US7148207	Oral fludara of high-purity formulation with quick release of active ingredient	Dec 20, 2022 (Expired)	Sanofi Aventis Us
Oforta	US7547776	Process for the production of fludarabine-phosphate lithium, sodium, potassium, calcium and magnesium salts and purification process for the production of fludarabine-phosphate and fludarabine-phosphate with a purity of at least 99.5%	Dec 10, 2018 (Expired)	Sanofi Aventis Us

Add above patents to watchlist

Fludarabine Phosphate's Family Patents

Full family tree

Fludarabine Phosphate Generic API Manufacturers

Several generic applications have been filed for Fludarabine Phosphate. The first generic version for Fludarabine Phosphate was by Hikma Pharmaceuticals Usa Inc and was approved on Aug 28, 2003. And the latest generic version is by Actavis Llc and was approved on Feb 28, 2017.

Given below is the list of companies who have filed for Fludarabine Phosphate generic, along with the locations of their manufacturing plants worldwide.